Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists

(2019) Daniela Roell et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

(2019) Amanda B. Pilling et al.   PROSTATE

Hsp90 inhibitors as senolytic drugs to extend healthy aging

(2018) Heike Fuhrmann-Stroissnigg et al.   CELL CYCLE

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

(2018) Benjamin A Teply et al.   LANCET ONCOLOGY

Interference with the androgen receptor protein stability in therapy-resistant prostate cancer

(2018) Gopinath Lakshmana et al.   INTERNATIONAL JOURNAL OF CANCER

Application of ex-vivo spheroid model system for the analysis of senescence and senolytic phenotypes in uterine leiomyoma

(2018) Jia Xie et al.   LABORATORY INVESTIGATION

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma

(2018) Nada M. S. Al-Saffar et al.   BRITISH JOURNAL OF CANCER

Identification of HSP90 inhibitors as a novel class of senolytics

(2017) Heike Fuhrmann-Stroissnigg et al.   Nature Communications

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling

(2016) Mohsen Esmaeili et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells

(2016) Mohsen Esmaeili et al.   Journal of Molecular Cell Biology

Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells

(2016) Avigail Dreazen Wittenberg et al.   PLoS One

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

(2015) P. N. Lara et al.   CLINICAL CANCER RESEARCH

Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms

(2015) Margaret M Centenera et al.   ENDOCRINE-RELATED CANCER

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer

(2015) Sven Perner et al.   Oncotarget

Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway

(2014) Julia Roediger et al.   Molecular Cancer

A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells

(2014) Wiebke Hessenkemper et al.   MOLECULAR ENDOCRINOLOGY

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors

(2014) Weisheng Zhang et al.   Translational Oncology

The beginning of the end

(2013) Judith Campisi   NATURE

Aging, Cellular Senescence, and Cancer

(2012) Judith Campisi   Annual Review of Physiology

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model

(2012) N. Floc'h et al.   CANCER RESEARCH

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

(2012) SUQIN HE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions

(2012) Keith F. Decker et al.   NUCLEIC ACIDS RESEARCH

Androgen Receptor Drives Cellular Senescence

(2012) Yelena Mirochnik et al.   PLoS One

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth

(2010) Manolis A. Fousteris et al.   BIOORGANIC & MEDICINAL CHEMISTRY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling

(2008) Y-J Jeon et al.   ONCOGENE

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY

An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β,17β-diol

(2007) Robert J. Handa et al.   HORMONES AND BEHAVIOR